Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer by Sáenz-López, Pablo et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes 
in patients with prostate cancer
Pablo Sáenz-López†1, Rafael Carretero†1, José Manuel Cózar2, 
José Maria Romero1, Julia Canton1, José Ramón Vilchez1, Miguel Tallada2, 
Federico Garrido and Francisco Ruiz-Cabello*1
Address: 1Servicio de Análisis Clínicos e Inmunología, Hospital Universitario Virgen de las Nieves, Granada, Spain and 2Servicio de Urología, 
Hospital Universitario Virgen de las Nieves, Granada, Spain
Email: Pablo Sáenz-López - pablosaenz-lopez@hotmail.com; Rafael Carretero - rafannel@hotmail.com; 
José Manuel Cózar - cozarjm@yahoo.es; José Maria Romero - josemariaromero@cofgranada.com; Julia Canton - julia.canton@gmail.com; 
José Ramón Vilchez - jrvilchez2000@gmail.com; Miguel Tallada - miguel.tallada.sspa@juntadeandalucia.es; 
Federico Garrido - federico.garrido.sspa@juntadeandalucia.es; Francisco Ruiz-Cabello* - fruizc@ugr.es
* Corresponding author    †Equal contributors
Abstract
Background: Inflammation has been implicated as an etiological factor in several human cancers,
including prostate cancer. Allelic variants of the genes involved in inflammatory pathways are logical
candidates as genetic determinants of prostate cancer risk. The purpose of this study was to
investigate whether single nucleotide polymorphisms of genes that lead to increased levels of pro-
inflammatory cytokines and chemokines are associated with an increased prostate cancer risk.
Methods: A case-control study design was used to test the association between prostate cancer
risk and the polymorphisms TNF-A-308 A/G (rs 1800629), RANTES-403 G/A (rs 2107538), IL1-A-
889 C/T (rs 1800587) and MCP-1 2518 G/A (rs 1024611) in 296 patients diagnosed with prostate
cancer and in 311 healthy controls from the same area.
Results: Diagnosis of prostate cancer was significantly associated with TNF-A GA + AA genotype
(OR, 1.61; 95% CI, 1.09–2.64) and RANTES GA + AA genotype (OR, 1.44; 95% CI, 1.09–2.38). A
alleles in TNF-A and RANTES influenced prostate cancer susceptibility and acted independently of
each other in these subjects. No epistatic effect was found for the combination of different
polymorphisms studied. Finally, no overall association was found between prostate cancer risk and
IL1-A or MCP-1 polymorphisms.
Conclusion:  Our results and previously published findings on genes associated with innate
immunity support the hypothesis that polymorphisms in proinflammatory genes may be important
in prostate cancer development.
Background
Chronic or recurrent inflammation is known to play a
causative role in the promotion and progression of many
human tumours, including cancers of the liver, oesopha-
gus, stomach, large intestine and urinary bladder [1-3].
Chronic inflammation has also been implicated in the
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aetiology of prostate cancer [4-7]. Prostate cancer risk has
been associated with sexually transmitted infections and
prostatitis in some epidemiologic studies [8,9], and its
relationship with genetic polymorphisms in inflamma-
tory cytokines has been explored in various case-control
studies [10-13]. Chronic inflammation, alongside the
intrinsic properties of pre-malignant cells and other deter-
minants, may therefore be one of the driving forces of
malignant transformation. Thus, numerous mediators
released in dysregulated chronic inflammation have been
found to promote cell growth and invasion, induce muta-
genesis and increase angiogenicity [1]. By virtue of these
properties, inflammatory mediators favour initiation of
malignancy, and if sustained, may also promote progres-
sion. In general, many inflammatory conditions are char-
acterized by the recruitment of inflammatory cells,
predominantly macrophages, due to the wide variety of
bioactive products they release. Cytokines and chemok-
ines produced by activated innate immune cells are the
most important components orchestrating the inflamma-
tory-tumour-microenviroment [14]. Most studies have
focussed on inflammatory chemokines that promote
monocyte migration, primarily MCP-1 and also RANTES
(regulated upon activation, normally T cell-expressed and
presumably secreted) [15-17]. Full activation of NF-κB in
inflammatory leukocytes resident in preneoplastic sites
are likely to exacerbate local M1-inflammation (high TNF-
A, high IL-1, high IL-12, low IL-10, low TGF-β) and favour
tumourigenesis [18]. In particular, pro-inflammatory
cytokines (e.g. IL-1 and TNF), can themselves affect cancer
risk [1,5,8,19].
In the present investigation, we studied the role of several
polymorphisms reported to have functional and biologi-
cal relevance in the inflammatory process. The SNPs
selected for study have all been found to influence the
expression of their respective cytokine in vitro.
TNF is a key mediator of inflammation and may contrib-
ute to tumour initiation by stimulating production of gen-
otoxic molecules, which can lead to DNA damage and
mutations [20]. Inter-individual variations in TNF-A lev-
els have been attributed to polymorphisms, notably the A
allele at -308 (G/A) position in the promotor region of the
TNF gene, which has been associated with higher TNF-A
transcription levels [21] and an increased risk of several
types of cancer [22]. However, findings on TNF-A poly-
morphisms in prostate cancer have been inconsistent [10-
13]. In fact, evaluation of genetic variation in cytokines
and chemokines in relation to inflammation and cancer
risk is a complex task. Thus, it is important to investigate
the possible role of other genes involved in the inflamma-
tion pathway that might influence prostate cancer risk.
Proinflammatory cytokines IL-1A and IL-1B [23,24] are
also produced by monocytes, macrophages and epithelial
cells and exhibit similar biological characteristics to TNF-
A, including participation in host response to microbial
invasion, inflammation and tissue injury [20]. IL-1 poly-
morphisms have also been linked to gastric [25], hepato-
cellular [26], lung [27], colorectal [28], vulvar [29] and
ovarian [30] cancers. Allele T of the IL1 (-889 C>T) poly-
morphism has been associated with high production of
this cytokine [31].
RANTES chemokine is believed to play a role in antitu-
mour immunity via immune cell recruitment [32]. Poly-
morphisms in RANTES  have been associated with a
higher risk of pancreatic cancer, supporting the hypothesis
that proinflammatory gene polymorphisms, in combina-
tion with proinflammatory conditions, may influence the
development of pancreatic cancer [33].
Finally, MCP-1, a member of the CC chemokine family,
possesses chemotactic activity for monocytes and T lym-
phocytes [34,35] and has been proposed to play a key role
in macrophage recruitment, expression of angiogenic fac-
tors and activation of matrix metalloproteinases in breast
cancer patients. Genetic variants within regulatory regions
of MCP-1 that affect transcription and protein production
have been correlated with the risk of breast cancer metas-
tasis [36]. This finding is consistent with the previously
reported overexpression of MCP-1 in breast cancer tissue
[37].
These cytokines and chemokines were selected for our
study because they are released in response to various
forms of cellular stress, including inflammation and car-
cinogen exposure. The objective of this study was to assess
the influence of genetic polymorphism of RANTES, MCP-
1, IL-1A and TNF-A on the risk of prostate cancer.
Methods
Patient samples
The study included adult males with a recent diagnosis of
prostate cancer (n = 296) referred to our hospital between
2002 and 2007. Clinical diagnosis of primary adenocarci-
noma of the prostate was histopathologically confirmed
after abnormal serum PSA findings and/or lower urinary
tract symptoms. Patients were unrelated Caucasian men
with a mean age of 67.4 ± 5.8 yrs and mean PSA level of
31.6 ± 5.7 (Table 1). Healthy unrelated Caucasian men (n
= 311) were enrolled as controls; these were recruited
from among blood donors on the Spanish Bone Marrow
Donor Registry of the same geographic region and with no
history of prostate cancer according to Registry records.
The mean of age of the controls was 44 ± 11 yrs. The clin-
ical characteristics of study participants are presented in
Table 1. The patients were classified according to their dis-BMC Cancer 2008, 8:382 http://www.biomedcentral.com/1471-2407/8/382
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ease progression, Gleason score and PSA level. Peripheral
blood samples were drawn from all participants into
tubes containing K3-EDTA. All subjects were interviewed
by a researcher and signed their informed consent to par-
ticipation in the study, which was approved by the Ethics
Committee of our hospital.
DNA samples and genotyping
Total genomic DNA was isolated from peripheral blood of
prostate cancer patients and healthy controls using the
QIAamp DNA Mini kit. SNPs samples were genotyped by
means of a Taqman 5' allelic discrimination assay. The
PCR and genotype of each sample was automatically
attributed by measuring the allelic specific fluorescence
on 500 PCR-REAL TIME Sequence Detection System using
SDS 2.2.1 software for allelic discrimination (Applied Bio-
systems, Foster City, CA, USA). Single nucleotide poly-
morphism amplification assays were used according to
the manufacturer's instructions. Briefly, 10 ng of sample
DNA(1 μl) were placed in 4 μl of reaction solution con-
taining: 2.5 μl of the 2× TaqMan® Universal PCR Mix
(Applied Biosystems), 0.25 μl of predevel ped assay rea-
gent from the SNP genotyping product(20×) (Applied
Biosystems) containing two primers and two MGB-Taq-
man probes, and 1.25 μl of distilled water. Reaction con-
ditions of the PCR were: preincubation at 50°C for 2 min
and at 95°C for 10 min, followed by 40 cycles of 95°C, 15
s; 60°C, 1 min. The polymorphisms studied were: TNF-
Table 1: Clinical caracteristics of prostate cancer patients.
Case Subjects No. (%) Case Subjects No. (%)
Variables Variables
Age at study Gleason Score
<60 51 <4 15 5
60–69 140 4–6 122 41.2
70–79 89 7–8 133 45
>80 16 9–10 26 8.8
T Stage Differential Grade
T1 25 8.5 1 25 8.5
T2 112 37.8 2 245 82.7
T3 111 37.5 3 26 8.8
T4 48 16.2 PSA levels, ng/ml
N Stage <10 69 23.3
N0 187 63.2 10–19.99 68 23
N1 109 36.8 20–20.99 39 13.2
M Stage 30–30.99 20 6.7
M0 226 76.3 40–40.99 18 6
M1 70 23.7 50–50.99 22 7.4
60–99.99 39 13.2
>100 21 7BMC Cancer 2008, 8:382 http://www.biomedcentral.com/1471-2407/8/382
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308 A/G (rs 1800629) SNP, RANTES-403 G/A (rs
2107538) SNP, IL-1A-889 C/T (rs 1800587) SNP, and
MCP-1 2518 G/A (rs 1024611) SNP. We studied the pol-
ymorphism in the promoter region that affects its tran-
scriptions. Thus, in RANTES, polymorphism A/G in
region -403 of the promoter was studied; the A allele is
associated with higher transcription [38]. In MCP-1, poly-
morphism A/G in region -2518 of the promoter was stud-
ied; the G allele produces much higher MCP-1 expression
[39]. In IL1-A, polymorphism C/T in region -889 of the
promoter was studied; the T allele causes higher IL1-A
expression[31]. In TNF-A, polymorphism G/A of region -
308 of the promoter was studied; the A allele produces
higher TNF-A expression [40].
Statistical analyses
Data were compiled according to the genotype and allele
frequencies estimated from the observed number of each
specific allele. SNPs allele frequencies were tested against
Hardy-Weinberg equilibrium by comparing observed
with expected genotype frequencies using a χ2 test. The
present study has a power higher than 95% to detect an
Odds Ratio (OR) of 2 in all analyses (measured by
Episheet programme). Genotype frequencies were com-
pared in 2 × 2 tables with the χ2 test. The strength of asso-
ciation was estimated by calculating ORs with 95% CI and
p values. Binary logistic regression analysis was used to
confirm differences in SNP frequencies between cases and
controls. Interaction analysis was calculated by logistic
binary regression. The SPSS v.15.0 software package was
used for the statistical analyses.
Results
The study included 296 patients recently diagnosed with
prostate cancer and 311 blood donors (controls). Table 2
shows the genotype and allelic distributions of the poly-
morphisms in cases and controls, with estimated ORs.
None of the SNP genotype frequencies deviated from
Hardy-Weinberg equilibrium, and the distributions of
alleles in the control group were in agreement with find-
ings in other Spanish Caucasian populations [41]. Poly-
morphisms could sometimes not be genotyped because of
PCR amplification problems, explaining discrepancies in
the numbers of cases among groups. Associations were
obtained by comparing with the control population (not
age-matched). Comparison of TNF-A promoter polymor-
phisms between patients and controls revealed statisti-
cally significant differences in genotype distribution for
locus -308, with a higher frequency of A carriers (AA/AG)
in patients than in controls (OR = 1.61; 95% CI: 1.09–
2.64 p = 0.017). Patients also showed a higher frequency
of A allele in the RANTES -403 G/A polymorphism versus
controls (OR = 1.44; 95% CI: 1.09–2.38 p = 0.039). In
contrast, MCP-1 2518 G/A and IL-1 A- 889 T allele geno-
types showed no significant differences between prostate
cancer and control groups (Table 2), suggesting that these
two genotypes may not play a role in susceptibility to
prostate cancer.
We stratified the data, grouping subjects according to their
carrier status for IL1-A allele T, TNF-A allele A, RANTES
allele A and MCP-1 allele G. In logistic regression analy-
ses, no significant association with prostate cancer risk
was found for IL1 or MCP-1 allele carrier status, but sub-
jects with AG or AA genotypes for TNF-A or RANTES had
increased prostate cancer risk versus those with GG geno-
type (Table 2). The combination of the A allele of TNF and
RANTES markedly increased this risk (OR, 2.45; 95% CI,
1.22 – 4.94, p = 0.012), although no epistatic effect (p =
0.416) was observed between these polymorphisms. SNP
genotypes were also compared within the patient group
and stratified according to tumour stage and serum PSA
level (Table 1) to determine whether the genotypes influ-
enced these indicators. No significant associations were
observed.
Discussion
Several polymorphisms have been associated with the
severity of or susceptibility to numerous inflammatory
diseases. In this case-control study, we investigated the
association between polymorphisms in cytokine/chem-
okine genes (TNF-A -308 G/A, RANTES-403 G/A, IL-1A -
889 C/T and MCP-1 2518 G/A) and prostate cancer risk.
Reports on TNF-A gene polymorphisms and prostate can-
cer have been controversial [10-13]. Our results suggest
that the A allele, associated with a high production of
TNF-A, is linked to an increased risk for prostate cancer.
TNF-A, a major factor in the inflammation response, has
been related to many types of cancer, e.g., T-cell large
granular lymphocyte leukaemia [42], cholestatic liver can-
cer, multiple myeloma, bladder cancer, hepatocellular
carcinoma, gastric cancer and breast cancer [22]. How-
ever, no association has been described with nasopharyn-
geal carcinoma [43] or cervix carcinoma [44].
Discrepancies in some previously published results for
TNF-A gene polymorphisms in prostate cancer may be
related to the modest risk found. Inflammation is a highly
complex process that involves hundreds of genes. The fact
that numerous gene polymorphisms contribute to the
inflammatory response adds further complexity to the
analysis of a specific polymorphism, because each indi-
vidual gene is likely to contribute only modestly to the
risk. Thus, TNF-A may interact in important ways with
multiple cytokine/chemokines involved in inflammation
pathways that also display genetic variation.
The discrepant results may be explained by the effects of
genetic heterogeneity and different gene-environment
interactions. Although the distribution of -308A TNF-A
has been found to vary among control groups due to eth-BMC Cancer 2008, 8:382 http://www.biomedcentral.com/1471-2407/8/382
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nic variations [44], the distribution of the allelic frequen-
cies in our study was similar to a recent report [13]. The
influence of other (non-inflammation-related) genes or
environmental factors is more likely to account for differ-
ences. Thus, there is evidence that prostate cancer has a
complex and multifactorial aetiology, which might
explain discrepancies in the attribution of prostate cancer
risk to a single SNP [45]. Furthermore, discrepant results
between the NorthAmerican [13] and the present study
might be influenced by differences in diet, lifestyle and
NSAID use between the study populations.
In this context, differences in NF-kB polymorphism were
reported between Spanish and North American groups in
association with ulcerative colitis [46]. Finally, a Sweden
Study [47,48] found that increased risk for this type of
Table 2: Statistical analysis of allele and genotype distributions of IL1A, MCP-1, RANTES and TNF-A polymorphisms.
Genotype 
frequencies
Control
n = 311
Case
n = 298
Genotype results p value OR 95% confidence 
interval
Interaction análysis
n% n %
Il-1 CC 152 50.2 133 44.9 Il-1 CT/TT versus CC 
[25]
0.200 1.23 0.89 – 1.82
Il-1 CT/TT 151 49.8 163 55.1
TNF-alpha GG 256 82.6 221 74.7 TNF-alpha AG/AA 
versus GG [13]
0.017 1.61 1.09 – 2.64
TNF-alpha AG/AA 54 17.4 75 25.3
MCP-1 AA 178 57.2 174 58.4 MCP-1 AG/GG versus 
AA [27]
0.770 0.95 0.66 – 1.33
MCP-1 AG/GG 133 42.8 124 41.6
RANTES GG 221 72.5 192 64.6 RANTES AG/AA versus 
GG [16]
0.039 1.44 1.09 – 2.38
RANTES AG/AA 84 27.5 105 35.4
TNF-alpha AG/AA and 
RANTES AG/AA
0.012 2.45 1.22 – 4.94 0.416
Allele frequencies Allele results
Il-1 C 426 70.3 401 67.5 Il-1 C versus Il-1 T 0.297 1.14 0.89–1.46
Il-1 T 180 29.7 193 32.5
TNF-alpha G 564 90.97 512 86.5 TNF-alpha G versus A 0.013 1.57 1.10–2.26
TNF-alpha A 56 9.03 80 13.5
MCP-1 A 479 77.01 448 75.2 MCP-1 A versus G 0.451 1.11 0.85–1.44
MCP-1 G 143 22.99 148 24.8
RANTES G 522 85.57 478 80.5 RANTES G versus A 0.018 1.44 1.03–1.95
RANTES A 88 14.43 116 19.5BMC Cancer 2008, 8:382 http://www.biomedcentral.com/1471-2407/8/382
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tumour is probably also influenced by other genes that
regulate inflammation (Toll-like receptor) and modify
individual susceptibility to prostate cancer. The combined
effect of several polymorphism loci is likely to markedly
increase the risk of prostate cancer.
Gene-cluster polymorphisms in the interleukin-1  (IL1B)
are associated with an increased risk of gastric and other
types of cancer [25,30,49]. However, no associations have
been found between polymorphisms in the IL1 gene clus-
ter (IL1A, IL1B and IL1R) and ovarian or breast cancer
[50,51]. Other authors reported no overall association
between IL-1 polymorphisms and gastric cancer [52], and
the reason for these different findings are unclear. The
present case-control study in Caucasian men found no
significant effect of IL1A (-889 C>T) gene polymorphisms
on prostate cancer risk.
Chemokines are also expressed in inflammation, attract-
ing and recruiting populations of immune effector cells to
injury or infection sites, and the relationship between
prostate cancer risk and polymorphisms of RANTES and
MCP-1 was investigated in this study. No link with the
MCP-1  polymorphism was observed, but a significant
association was found between the A allele of RANTES
and prostate cancer risk (p =  0.039). Allele A in RANTES
is associated with increased transcription, which is related
to inflammation and antitumour immunity via immune
cell recruitment [53]. The allele A of RANTES and TNF-A
has been associated with pancreatitis, especially as a pos-
sible early sign of pancreatic cancer [33]. In our study, the
same alleles (TNF-A and RANTES) were also associated
with a higher prostate cancer risk. Interestingly, the simul-
taneous presence of allele A of both genes promotes a
higher risk (OR = 2.45, p = 0.012) of cancer, but the inter-
action analysis showed no epistatic interaction between
them (p =  0.416), indicating that their effects were addi-
tive. Finally, our study has some evident limitations and
false positive results cannot be ruled out: thus, size of the
study population is relatively small, aged-matched con-
trols were not used and a possible bias corresponding to
age cannot be excluded. However, even if we would have
used a totally age-matched control subjects, our results
would have been with even higher significance, because in
this control group we cannot rule out a possibility that
some of the younger control subjects may develop pros-
tate cancer later in their life. In addition, there was no dif-
ference found between our control subjects and those
used from our geographic area in a study of age-related
diseases [54,55]. In general, we would like to comment
that the influence of age on the immune gene polymor-
phism remains controversial. Some publications indicate
that there are no differences in genotype distribution
between older and younger controls [56], whereas others
have reported an age-dependent difference in polymor-
phism of certain genes [57].
There is a need for studies of larger patient groups, includ-
ing other potential functional polymorphisms in linkage
disequilibrium to determine the role of these polymor-
phisms in prostate cancer.
Conclusion
In conclusion, our data suggest an important role for TNF-
A  and  RANTES  polymorphisms in prostate cancer, as
observed in many other types of cancer. Other genetic pol-
ymorphisms involved in innate immunity and chronic
inflammation have been associated with prostate cancer
[48], and the present findings support the hypothesis that
the inflammatory process may constitute an important
step in the initiation and promotion of prostate cancer.
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